Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus.


Journal

Journal of immunological methods
ISSN: 1872-7905
Titre abrégé: J Immunol Methods
Pays: Netherlands
ID NLM: 1305440

Informations de publication

Date de publication:
11 2019
Historique:
received: 03 04 2019
revised: 18 06 2019
accepted: 18 06 2019
pubmed: 23 6 2019
medline: 12 5 2020
entrez: 23 6 2019
Statut: ppublish

Résumé

The rabies rapid fluorescent focus inhibition test (RFFIT) is the most widely used cell-based assay for detecting and quantitating rabies virus neutralizing antibodies (RVNA) in human serum. However, it is a complex, labor intensive, and somewhat subjective manual assay, the performance of which may be affected by a number of factors including the quality of cells and virus, variability of assay reagents and the skill and expertise of analysts. This study sought to identify and evaluate conditions that may impact RFFIT performance and RVNA detection by evaluating assay parameters including: different serial dilution scheme of serum samples in a 96-well microplate using semi-automated pipetting systems, the range of dose of challenge virus standard (CVS-11) strain of rabies virus, the effect of complement (C'), the effect of cell seeding density and passage number, the effect of diethylaminoethyl (DEAE) dextran concentration on virus infectivity, and the assay incubation period prior to immunostaining. In addition the evaluation of counting fluorescent foci using a microscope versus using scanned images from a cell imaging reader was performed in an effort to ease the reading of slides and have permanent records of the raw data. The results from optimization of each parameter are presented along with subsequent assay validation in accordance with the International Conference on Harmonization (ICH) guidelines. The improved and optimized RFFIT accuracy, linearity and sensitivity was demonstrated by testing World Health Organization (WHO)-1 and WHO-2 Standard Rabies Immune Globulins (SRIGs) and complete assay development and validation was performed in compliance with Good Clinical Laboratory Practice (GCLP) guidelines.

Identifiants

pubmed: 31228423
pii: S0022-1759(19)30138-3
doi: 10.1016/j.jim.2019.06.017
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

112626

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Tatyana M Timiryasova (TM)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: tatyana.timiryasova@sanofi.com.

Ping Luo (P)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: ping.luo@sanofi.com.

Lingyi Zheng (L)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: lingyi.zheng@sanofi.com.

Amy Singer (A)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: amy.singer@sanofi.com.

Rebecca Zedar (R)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: rebecca.zedar@sanofi.com.

Sanjay Garg (S)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: sanjay.garg@sanofi.com.

Celine Petit (C)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: celine.petit@sanofi.com.

Susan Moore (S)

Kansas State Veterinary Diagnostic Laboratory at Kansas State University College of Veterinary Medicine, Manhattan, KS 66502, USA. Electronic address: smoore@vet.k-state.edu.

Branda T Hu (BT)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: hubranda@gmail.com.

Monique Brown (M)

Sanofi Pasteur, Discovery Drive, Swiftwater, PA 18370, USA. Electronic address: monique.brown@sanofi.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH